Cargando…

Environmental Designer Drugs: When Transformation May Not Eliminate Risk

[Image: see text] Environmental transformation processes, including those occurring in natural and engineered systems, do not necessarily drastically alter molecular structures of bioactive organic contaminants. While the majority of generated transformation products are likely benign, substantial c...

Descripción completa

Detalles Bibliográficos
Autores principales: Cwiertny, David M., Snyder, Shane A., Schlenk, Daniel, Kolodziej, Edward P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2014
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4204896/
https://www.ncbi.nlm.nih.gov/pubmed/25216024
http://dx.doi.org/10.1021/es503425w
_version_ 1782340619042029568
author Cwiertny, David M.
Snyder, Shane A.
Schlenk, Daniel
Kolodziej, Edward P.
author_facet Cwiertny, David M.
Snyder, Shane A.
Schlenk, Daniel
Kolodziej, Edward P.
author_sort Cwiertny, David M.
collection PubMed
description [Image: see text] Environmental transformation processes, including those occurring in natural and engineered systems, do not necessarily drastically alter molecular structures of bioactive organic contaminants. While the majority of generated transformation products are likely benign, substantial conservation of structure in transformation products can imply conservation or even creation of bioactivity across multiple biological end points and thus incomplete mitigation of ecological risk. Therefore, focusing solely on parent compound removal for contaminants of higher relative risk, the most common approach to fate characterization, provides no mechanistic relationship to potential biological effects and is inadequate as a comprehensive metric for reduction of ecological risks. Here, we explore these phenomena for endocrine-active steroid hormones, focusing on examples of conserved bioactivity and related implications for fate assessment, regulatory approaches, and research opportunities.
format Online
Article
Text
id pubmed-4204896
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-42048962015-09-12 Environmental Designer Drugs: When Transformation May Not Eliminate Risk Cwiertny, David M. Snyder, Shane A. Schlenk, Daniel Kolodziej, Edward P. Environ Sci Technol [Image: see text] Environmental transformation processes, including those occurring in natural and engineered systems, do not necessarily drastically alter molecular structures of bioactive organic contaminants. While the majority of generated transformation products are likely benign, substantial conservation of structure in transformation products can imply conservation or even creation of bioactivity across multiple biological end points and thus incomplete mitigation of ecological risk. Therefore, focusing solely on parent compound removal for contaminants of higher relative risk, the most common approach to fate characterization, provides no mechanistic relationship to potential biological effects and is inadequate as a comprehensive metric for reduction of ecological risks. Here, we explore these phenomena for endocrine-active steroid hormones, focusing on examples of conserved bioactivity and related implications for fate assessment, regulatory approaches, and research opportunities. American Chemical Society 2014-09-12 2014-10-21 /pmc/articles/PMC4204896/ /pubmed/25216024 http://dx.doi.org/10.1021/es503425w Text en Copyright © 2014 American Chemical Society Terms of Use (http://pubs.acs.org/page/policy/authorchoice_termsofuse.html)
spellingShingle Cwiertny, David M.
Snyder, Shane A.
Schlenk, Daniel
Kolodziej, Edward P.
Environmental Designer Drugs: When Transformation May Not Eliminate Risk
title Environmental Designer Drugs: When Transformation May Not Eliminate Risk
title_full Environmental Designer Drugs: When Transformation May Not Eliminate Risk
title_fullStr Environmental Designer Drugs: When Transformation May Not Eliminate Risk
title_full_unstemmed Environmental Designer Drugs: When Transformation May Not Eliminate Risk
title_short Environmental Designer Drugs: When Transformation May Not Eliminate Risk
title_sort environmental designer drugs: when transformation may not eliminate risk
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4204896/
https://www.ncbi.nlm.nih.gov/pubmed/25216024
http://dx.doi.org/10.1021/es503425w
work_keys_str_mv AT cwiertnydavidm environmentaldesignerdrugswhentransformationmaynoteliminaterisk
AT snydershanea environmentaldesignerdrugswhentransformationmaynoteliminaterisk
AT schlenkdaniel environmentaldesignerdrugswhentransformationmaynoteliminaterisk
AT kolodziejedwardp environmentaldesignerdrugswhentransformationmaynoteliminaterisk